pioglitazone has been researched along with Diabetic Retinopathy in 16 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 7.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 7.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "To explore the effects of pioglitazone on MKP-1 and TSP-1 expression in the early stages of diabetic retinopathy induced by streptozotocin (STZ) and the relevant mechanism in it." | 7.73 | [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]. ( Kong, JX; Shen, JG; Wang, JY, 2006) |
| "Treatment of pioglitazone also protected the secondary structural alterations induced by glycation and inhibited the formation of protein aggregates." | 5.72 | Ameliorative effect of pioglitazone on glucose induced glycation of α-crystallin: Management of complications associated with diabetic retinopathy. ( Ren, Z; Song, J, 2022) |
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 3.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 3.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "To observe the changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone and to elucidate the possible mechanism involved and the effects of thiazolidinediones compound pioglitazone on the early stages of diabetic retinopathy." | 3.74 | [The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone]. ( Shen, F; Wang, JY; Zhang, HY; Zhang, XM, 2007) |
| "To explore the effects of pioglitazone on MKP-1 and TSP-1 expression in the early stages of diabetic retinopathy induced by streptozotocin (STZ) and the relevant mechanism in it." | 3.73 | [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]. ( Kong, JX; Shen, JG; Wang, JY, 2006) |
| "Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines." | 2.74 | Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. ( Kumar, H; Mishra, M; Tripathi, K; Vijay, SK, 2009) |
| "Glycemic control in the context of type 2 diabetes, as well as prediabetes, is also intertwined with CV risk factors such as obesity, hypertriglyceridemia, and blood pressure control." | 2.47 | Macrovascular effects and safety issues of therapies for type 2 diabetes. ( Plutzky, J, 2011) |
| "Treatment of pioglitazone also protected the secondary structural alterations induced by glycation and inhibited the formation of protein aggregates." | 1.72 | Ameliorative effect of pioglitazone on glucose induced glycation of α-crystallin: Management of complications associated with diabetic retinopathy. ( Ren, Z; Song, J, 2022) |
| "Patients with type II diabetes mellitus were categorized into 2 groups depending on TZD intake." | 1.39 | Impact of thiazolidinediones on macular thickness and volume in diabetic eyes. ( Al Shaar, L; Azar, S; Bashshur, ZF; El-Mollayess, GM; Salti, HI, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, Z | 1 |
| Song, J | 1 |
| Wachal, Z | 1 |
| Bombicz, M | 1 |
| Priksz, D | 1 |
| Hegedűs, C | 1 |
| Kovács, D | 1 |
| Szabó, AM | 1 |
| Kiss, R | 1 |
| Németh, J | 1 |
| Juhász, B | 1 |
| Szilvássy, Z | 1 |
| Varga, B | 1 |
| Motohashi, Y | 1 |
| Kemmochi, Y | 1 |
| Maekawa, T | 1 |
| Tadaki, H | 1 |
| Sasase, T | 1 |
| Tanaka, Y | 1 |
| Kakehashi, A | 1 |
| Yamada, T | 1 |
| Ohta, T | 1 |
| Hoshikawa, Y | 1 |
| Ohkoshi, K | 1 |
| Azar, S | 1 |
| El-Mollayess, GM | 1 |
| Al Shaar, L | 1 |
| Salti, HI | 1 |
| Bashshur, ZF | 1 |
| Jiang, Y | 1 |
| Thakran, S | 2 |
| Bheemreddy, R | 1 |
| Ye, EA | 1 |
| He, H | 1 |
| Walker, RJ | 1 |
| Steinle, JJ | 2 |
| Zhang, Q | 1 |
| Morales-Tirado, V | 1 |
| Vijay, SK | 1 |
| Mishra, M | 1 |
| Kumar, H | 1 |
| Tripathi, K | 1 |
| Fong, DS | 1 |
| Contreras, R | 1 |
| Oshitari, T | 1 |
| Asaumi, N | 1 |
| Watanabe, M | 1 |
| Kumagai, K | 1 |
| Mitamura, Y | 1 |
| Higuchi, A | 1 |
| Ohashi, K | 1 |
| Shibata, R | 1 |
| Sono-Romanelli, S | 1 |
| Walsh, K | 1 |
| Ouchi, N | 1 |
| Omae, T | 1 |
| Nagaoka, T | 1 |
| Tanano, I | 1 |
| Yoshida, A | 1 |
| Plutzky, J | 1 |
| Kusuyama, T | 1 |
| Omura, T | 1 |
| Nishiya, D | 1 |
| Enomoto, S | 1 |
| Matsumoto, R | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Yoshiyama, M | 1 |
| Wang, JY | 2 |
| Shen, JG | 1 |
| Kong, JX | 1 |
| Zhang, HY | 1 |
| Zhang, XM | 1 |
| Shen, F | 1 |
1 review available for pioglitazone and Diabetic Retinopathy
| Article | Year |
|---|---|
Macrovascular effects and safety issues of therapies for type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Pro | 2011 |
1 trial available for pioglitazone and Diabetic Retinopathy
| Article | Year |
|---|---|
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; | 2009 |
14 other studies available for pioglitazone and Diabetic Retinopathy
| Article | Year |
|---|---|
Ameliorative effect of pioglitazone on glucose induced glycation of α-crystallin: Management of complications associated with diabetic retinopathy.
Topics: alpha-Crystallins; Cataract; Crystallins; Diabetes Mellitus; Diabetic Retinopathy; Glucose; Humans; | 2022 |
Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Ele | 2020 |
Diabetic macular edema-like ocular lesions in male spontaneously diabetic torii fatty rats.
Topics: Animals; Capillary Permeability; Diabetic Retinopathy; Disease Models, Animal; Hyperglycemia; Hypogl | 2018 |
[Association between pioglitazone and diabetic macular edema].
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Humans; Hypoglycemic Agents; Macular E | 2013 |
Impact of thiazolidinediones on macular thickness and volume in diabetic eyes.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gly | 2013 |
Pioglitazone normalizes insulin signaling in the diabetic rat retina through reduction in tumor necrosis factor α and suppressor of cytokine signaling 3.
Topics: Animals; Apoptosis; bcl-X Protein; Beta Rhythm; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic R | 2014 |
Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions.
Topics: Apoptosis; Blotting, Western; Cells, Cultured; Culture Media; Diabetic Retinopathy; DNA; DNA-Activat | 2014 |
Glitazone use associated with diabetic macular edema.
Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glycated Hemoglobin; Hum | 2009 |
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diuretics; Female; Fluorescein Angiography; | 2008 |
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Isch | 2010 |
Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels.
Topics: Animals; Arterioles; Calcium Channel Blockers; Diabetic Retinopathy; Dose-Response Relationship, Dru | 2011 |
Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.
Topics: Actins; Adult; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Complications; Diabetes | 2006 |
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hypoglycemic Agents; Mitogen-Activat | 2006 |
[The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Female; Gene Expression; Hypoglycemi | 2007 |